Phoenix Biotechnology, Inc. (PBI)'s Focus
While the prevention and treatment of human malignant disease remains PBI's primary focus, novel, patented extracts of Nerium oleander continue to reveal promising avenues of research showing activity against certain viral and neurodegenerative diseases.
2011 and 2009 ASCO
"Poster Discussion Group"
2009 SIO Intl' Conference
"Best of SIO"
"Technology Super Star"
"The Botanical Glycoside Oleandrin Inhibits Human T-cell Leukemia Virus Type-1 Infectivity and Env-Dependent Virological Synapse Formation". Robert Harrod, Tetiana Hutchison, Lacin Yapindi, Aditi Malu, Robert A Newman, K Jagannadha Sastry. Journal of Antivirals & Antiretrovirals, Published Date: 2019-09-02.
"Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1". Yong L, Ma Y, et al. Phtyother. Res. 2019 May.
This article shows that oleandrin enhances or synergizes with the standard of care chemotherapy agent cisplatin against osteosarcoma (bone) cancer.
Importance: Phoenix Biotechnology's drug PBI-05204 contains oleandrin as one of its main active ingredients and we have previously shown that it acts in a synergistic manner with chemotherapy drugs against a variety of different types of human malignant disease. New data being prepared for publication now shows the PBI-05204 is synergistic with Temozolamide and radiotherapy against glioblastoma, a difficult to treat form of brain cancer.